Dr. Michael Poulter, CSO of OB Pharmaceuticals to present at Eilat XIV.

LONDON, ONTARIO May 2, 2018 -- OB Pharmaceuticals was invited to present the details of its drug development program of oxynytones at the 14th Eilat Conference in Madrid, Spain May 13-16, 2018. Dr. Michael Poulter will discuss the unique differentiating properties of these novel compounds and the compelling preclinical evidence in support of their continued development as promising therapeutics for the treatment of epilepsy and other related seizure disorders.

About Eilat XIV
The Eilat Conference on New Antiepileptic Drugs and Devices will take place from 13th May to 16th May 2017 at the Melia Castilla Hotel & Convention Center in Madrid, Spain. The conference will cover areas like designed to provide an in-depth progress report on new antiepileptic drugs in various stages of development, as well as to present new findings on second-generation treatments. For more information: https://www.eilatxiv.com

About OB Pharmaceuticals
OB Pharmaceuticals is an early stage biopharmaceutical company dedicated to improving the lives of individuals through the development of first-in-class therapeutics for more effective prevention and management of epilepsy and other related seizure disorders.

Dr. Larry Mahan, VP Business Development to present at Biotech Showcase 2018

LONDON, ONTARIO January 2, 2018 -- Dr. Larry Mahan attended BioTech Showcase 2018 during JP Morgan week in San Francisco on behalf of OB Pharmaceuticals for 3 days of business partnering and a corporate presentation on the remarkable preclinical progress of the company's program on the development of oxynytones, novel molecules showing promise for the treatment and prevention of epilepsy and other related seizure disorders. More than twenty meetings transpired spanning business partnering and potential venture investment.

About BioTech Showcase
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its tenth year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. In addition to biopharmaceutical and life science company executives, Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry.

About OB Pharmaceuticals
OB Pharmaceuticals is an early stage biopharmaceutical company dedicated to improving the lives of individuals through the development of first-in-class therapeutics for more effective prevention and management of epilepsy and other related seizure disorders.

OB Pharmaceuticals to attend BioEurope Spring 2017

LONDON, ONTARIO March 10, 2017 -- Representatives from OB Pharmaceuticals attended BioEurope Spring 2017 in Barcelona, Spain, March 20-22 to meet with potential pharma and venture partners to expand development of its promising novel molecules for the treatment and prevention of epilepsy and other related seizure disorders.

About BioEurope Spring
With a focus on European innovation and global collaboration, BIO-Europe Spring is the premier springtime partnering conference from biotech, pharma and finance in the most innovative biopharma clusters in Europe. BIO-Europe Spring attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts.

About OB Pharmaceuticals
OB Pharmaceuticals is an early stage biopharmaceutical company dedicated to improving the lives of individuals through the development of first-in-class therapeutics for more effective prevention and management of epilepsy and other related seizure disorders.

OB Pharmaceuticals Logo epilepsy Brain trauma